ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.

What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
Personalized Breast Cancer Treatment Offered by Texas Breast Center Utilizes Agendia
Texas Breast Center, led by renowned breast surgeon Dr. Valerie Gorman, is pleased to announce the use of Agendia, a global leader in genomic testing. This collaboration aims to provide patients with the most Read More
Hormonal Therapy Story: How Laura-Lynn Renner Made an Informed Choice
By Kris Conner | August 7, 2024 How the diagnostic test MammaPrint empowered Laura-Lynn to find answers and advocate to improve the quality of her life. In the summer of 2020, Laura-Lynn Renner, a Read More
What Is Chemotherapy?
Along with surgery or radiation therapy, chemotherapy is one of the most common ways to treat cancer. Chemotherapy treatment is designed to destroy cancer cells; it can be used for primary cancer (cancer that Read More
Anthracycline Plus Chemo Associated With Improved RFS in MP High-2โRisk, HR+/HER2โ Early Breast Cancer
By Ryan Scottย June 1, 2024 Key Takeaways Patients with MammaPrint high-2, BluePrint Luminal B, HR-positive, HER2-negative early breast cancer had better 3-year RFS with anthracycline plus a taxane and cyclophosphamide. Luminal MP high-1โrisk Read More
News
Media Releases
Agendia to Unveil Robust Suite of Data at 2024 ASCO
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Read MoreGerman Gynecological Oncology Group (AGO) includes BluePrintยฎ in Guidelines
German Gynecological Oncology Group (AGO) Recognizes BluePrintยฎ in Breast Cancer Guidelines
Read MoreAgendia Announces New I-SPY2 Data Showcasing Ability of New Signature ImPrintTN
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
Read MoreAgendia Presents Data from FLEX Study at Miami Breast 2024
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrintยฎ + BluePrintยฎโs Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
Read More